Sign In
Buy ILMN
$170.93
+8.38 (+5.16%)
At Close: Jun 03, 2026
Illumina (ILMN) Launches Genomic Solution Hub in Brazil
11:17am, Wednesday, 13'th Apr 2022
Illumina's (ILMN) customers and partners in Brazil currently span basic research, applied markets to clinical labs and healthcare institutions.
3 Things About Pacific Biosciences of California That Smart Investors Know
12:25pm, Tuesday, 12'th Apr 2022 The Motley Fool
Anyone thinking about buying shares should know them, too.
Illumina: A Good Long-Term BioTech Investment
02:29am, Saturday, 09'th Apr 2022
COVID-19 crippled the sales of major players in life-science technology.
Chemistry X, Infinity, GRAIL: The New Illumina Is A Buy
06:09am, Friday, 08'th Apr 2022 Seeking Alpha
Illumina's base business is running at peak performance. Illumina's Chemistry X promises to launch its business onto a whole new trajectory. Despite some negatives, I rate it as a Buy.
Chemistry X, Infinity, GRAIL: The New Illumina Is A Buy
02:09am, Friday, 08'th Apr 2022
Illumina's base business is running at peak performance. Illumina's Chemistry X promises to launch its business onto a whole new trajectory.
Here Are 2 Pieces of Good News for Illumina
12:00pm, Thursday, 07'th Apr 2022 The Motley Fool
This gene-sequencing leader looks poised to benefit from a pair of long-term trends.
Why Guardant Health Stock Soared Nearly 10% Higher Today
08:20pm, Friday, 01'st Apr 2022 The Motley Fool
Negativity surrounding the precision oncology company might be overblown.
Tekla Healthcare Investors: A Dividend Paymaster That Can Compensate For Poor Price Performance
11:31pm, Tuesday, 29'th Mar 2022
Tekla Healthcare Investors: A Dividend Paymaster That Can Compensate For Poor Price Performance
Analyst Ratings For Illumina
05:03pm, Tuesday, 29'th Mar 2022 Benzinga
Illumina (NASDAQ:ILMN) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
1
4
1
0
Last 30D
0
0
Benzinga's Top Ratings Upgrades, Downgrades For March 29, 2022
02:04pm, Tuesday, 29'th Mar 2022 Benzinga
Upgrades
According to OTR Global, the prior rating for Illumina Inc (NASDAQ:ILMN) was changed from Mixed to Positive. For the fourth quarter, Illumina had an EPS of $0.75, compared to year-ago quarter
Illumina (ILMN) Debuts TSO Comprehensive Test in Europe
02:30pm, Friday, 18'th Mar 2022 Zacks Investment Research
Illumina's (ILMN) novel CE-marked IVD kit for comprehensive genomic profiling will enable clinicians to match cancer patients with available therapies.
Illumina (ILMN) Invests in Seven Additional Genomics Startups
02:08pm, Friday, 18'th Mar 2022 Zacks Investment Research
Illumina's (ILMN) investment in seven new genomics companies is intended to advance breakthrough therapeutics, diagnostics, DNA storage, mental wellness and sustainable foods applications.
Illumina (ILMN) Debuts TSO Comprehensive Test in Europe
12:02pm, Friday, 18'th Mar 2022
Illumina's (ILMN) novel CE-marked IVD kit for comprehensive genomic profiling will enable clinicians to match cancer patients with available therapies.
Illumina invests in 7 startups focused on breakthrough therapies, diagnostics
03:58pm, Wednesday, 16'th Mar 2022 Seeking Alpha
Illumina (ILMN) said it has invested in seven new startups advancing breakthrough therapeutics, diagnostics, DNA storage, mental wellness, and sustainable foods…
Illumina launches cancer gene profiling test TruSight for precision treatment in Europe
10:08am, Tuesday, 15'th Mar 2022 Seeking Alpha
Illumina (ILMN) launched the TruSight Oncology Comprehensive test in Europe that assesses multiple tumor genes and biomarkers to potentially help patients get matched with…
